Engineered biosynthetic pathway for sialic acid analogs and its use for the development of anti-infectives

Download
  1. (PDF, 297 KB)
AuthorSearch for: ; Search for:
TypePresentation
Proceedings titleThe Crossroad for Biotransfer 2010
ConferenceThe Crossroad for Biotransfer 2010, May 18, 2010, Boston, Massachusetts, USA
Physical description1 p.
AbstractThere is clearly an unmet need for anti-influenza drugs that are more effective than those currently available, and ideally that are effective against various strains of influenza and that are not prone to the development of resistance. The unique features of the NRC-IBS technology, with its anticipated efficacy against numerous strains, possibly including avian flu, will enable it to compete effectively against such products. We also note that the market is quite large, and is likely to continue to grow over the coming years. The technology may also result in the development of agents against other viral infections, and against bacterial infections.
Publication date
PublisherNational Research Council
LanguageEnglish
AffiliationNRC Institute for Biological Sciences; National Research Council Canada
Peer reviewedYes
NPARC number17442572
Export citationExport as RIS
Report a correctionReport a correction
Record identifier0c36bca9-da1a-48cd-9eff-b526aceb2556
Record created2011-04-08
Record modified2017-05-11
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)